on February 24, 2005
Published online before print February 24, 2005, doi: 10.1161/01.STR.0000157668.39374.56
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 7, 2004
Background and Purpose--Because of its success in treatment of acute cardiac ischemia, there is interest in the use of abciximab for treating patients with acute ischemic stroke. A previous dose-escalation study determined that abciximab could be given safely in a regimen of 0.25 mg/kg intravenous bolus followed by a 12-hour infusion at 0.125 µg/kg per minute (maximum 10 µg/min). This study was performed to obtain more information about the safety and potential efficacy of abciximab in patients with stroke. Methods--An international randomized, double-blind, placebo-controlled phase 2 trial enrolled 400 patients within 6 hours of onset of ischemic stroke. The primary safety outcome was the rate of symptomatic hemorrhage that occurred during the first 5 days after stroke. The primary efficacy measure was the distribution of outcomes at 3 months after stroke using the modified Rankin Scale (mRS) based on an ordinal regression model of outcomes, adjusting for baseline severity of stroke, age, and interval from stroke. Results--Symptomatic intracranial hemorrhage within 5 days was diagnosed in 7 of 195 (3.6%) patients treated with abciximab and 2 of 199 (1%) patients given placebo (odds ratio [OR], 3.7; P=0.09; 95% confidence interval [CI], 0.7 to 25.9). Asymptomatic hemorrhagic transformation was detected by brain imaging in 24 patients administered abciximab and 33 patients receiving placebo (OR, 0.74; P=0.25; 95% CI, 0.4 to 1.3). Treatment with abciximab showed a nonsignificant shift in favorable outcomes as measured by mRS scores at 3 months (OR, 1.20; P=0.33; 95% CI, 0.84 to 1.70). Conclusions--Intravenously administered abciximab can be given to patients with a reasonable degree of safety. The trial also suggests that abciximab could improve outcomes at 3 months after stroke. A larger randomized, double-blind, placebo-controlled trial is necessary to test the efficacy of abciximab.
Revised on December 1, 2004
Accepted on December 21, 2004
Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke. Results of a Randomized Phase 2 Trial
Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators
Key words: antiplatelet agents • emergency medical treatment • stroke
This article has been cited by other articles:
 |
|
 |
|
  P. Mandava and T. A. Kent A Method to Determine Stroke Trial Success Using Multidimensional Pooled Control Functions Stroke, May 1, 2009; 40(5): 1803 - 1810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. Wasiewski To Phase 3 or Not to Phase 3? Stroke, May 1, 2009; 40(5): 1553 - 1554. [Full Text] [PDF]
|
|
|
|
|
|
T. Ries, S. Siemonsen, U. Grzyska, H. Zeumer, and J. Fiehler Abciximab Is a Safe Rescue Therapy in Thromboembolic Events Complicating Cerebral Aneurysm Coil Embolization: Single Center Experience in 42 Cases and Review of the Literature Stroke, May 1, 2009; 40(5): 1750 - 1757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Arsava, R. Rahman, J. Rosand, J. Lu, E. E. Smith, N. S. Rost, A. B. Singhal, M. H. Lev, K. L. Furie, W. J. Koroshetz, et al. Severity of leukoaraiosis correlates with clinical outcome after ischemic stroke Neurology, April 21, 2009; 72(16): 1403 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Optimising the Analysis of Stroke Trials (OAST Should Stroke Trials Adjust Functional Outcome for Baseline Prognostic Factors? Stroke, March 1, 2009; 40(3): 888 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, E. C. Leira, J. C. Torner, E. Barnathan, L. Padgett, M. B. Effron, W. Hacke, and for the AbESTT-II Investigators Treating Patients With 'Wake-Up' Stroke: The Experience of the AbESTT-II Trial Stroke, December 1, 2008; 39(12): 3277 - 3282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 630S - 669S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Baumgartner, D. Georgiadis, K. Nedeltchev, G. Schroth, H. Sarikaya, and M. Arnold Stent-Assisted Endovascular Thrombolysis Versus Intravenous Thrombolysis in Internal Carotid Artery Dissection With Tandem Internal Carotid and Middle Cerebral Artery Occlusion Stroke, February 1, 2008; 39(2): e27 - e28. [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, M. B. Effron, J. Torner, A. Davalos, J. Frayne, P. Teal, J. Leclerc, B. Oemar, L. Padgett, E. S. Barnathan, et al. Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of an International Phase III Trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II) Stroke, January 1, 2008; 39(1): 87 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Schellinger, G. Thomalla, J. Fiehler, M. Kohrmann, C. A. Molina, T. Neumann-Haefelin, M. Ribo, O. C. Singer, O. Zaro-Weber, and J. Sobesky MRI-Based and CT-Based Thrombolytic Therapy in Acute Stroke Within and Beyond Established Time Windows: An Analysis of 1210 Patients Stroke, October 1, 2007; 38(10): 2640 - 2645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Saver Hemorrhage After Thrombolytic Therapy for Stroke: The Clinically Relevant Number Needed to Harm Stroke, August 1, 2007; 38(8): 2279 - 2283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Optimising Analysis of Stroke Trials (OAST) Co Can We Improve the Statistical Analysis of Stroke Trials?: Statistical Reanalysis of Functional Outcomes in Stroke Trials * OAST Supplemental Appendix I: Statistical Tests Compared (see Table I) * OAST Supplemental Appendix II: Supplementary Analyses * OAST Supplemental Appendix III: Trial Data (see Tables II and III) * OAST Supplemental Appendix IV: Results (see Table IV) Stroke, June 1, 2007; 38(6): 1911 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Mikulik, M. Ribo, M. D. Hill, J. C. Grotta, M. Malkoff, C. Molina, M. Rubiera, R. Delgado-Mederos, J. Alvarez-Sabin, A. V. Alexandrov, et al. Accuracy of Serial National Institutes of Health Stroke Scale Scores to Identify Artery Status in Acute Ischemic Stroke Circulation, May 22, 2007; 115(20): 2660 - 2665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Alonso, A. Della Martina, M. Stroick, M. Fatar, M. Griebe, S. Pochon, M. Schneider, M. Hennerici, E. Allemann, and S. Meairs Molecular Imaging of Human Thrombus With Novel Abciximab Immunobubbles and Ultrasound Stroke, May 1, 2007; 38(5): 1508 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kleinschnitz, M. Pozgajova, M. Pham, M. Bendszus, B. Nieswandt, and G. Stoll Targeting Platelets in Acute Experimental Stroke: Impact of Glycoprotein Ib, VI, and IIb/IIIa Blockade on Infarct Size, Functional Outcome, and Intracranial Bleeding Circulation, May 1, 2007; 115(17): 2323 - 2330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Khatri, L. R. Wechsler, and J. P. Broderick Intracranial Hemorrhage Associated With Revascularization Therapies Stroke, February 1, 2007; 38(2): 431 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mandava, J. A. Anderson, and T. A. Kent MRI-guided, open trial of abciximab for ischemic stroke within a 3- to 24-hour window Neurology, April 11, 2006; 66(7): 1132 - 1132. [Full Text] [PDF]
|
|
|
|
|
|
M. Ribo, J. Alvarez-Sabin, J. Montaner, F. Romero, P. Delgado, M. Rubiera, R. Delgado-Mederos, and C. A. Molina Temporal Profile of Recanalization After Intravenous Tissue Plasminogen Activator: Selecting Patients for Rescue Reperfusion Techniques Stroke, April 1, 2006; 37(4): 1000 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Ringleb Thrombolytics, Anticoagulants, and Antiplatelet Agents Stroke, February 1, 2006; 37(2): 312 - 313. [Full Text] [PDF]
|
|
|
|
|
|
A. Abou-Chebl, C. T. Bajzer, D. W. Krieger, A. J. Furlan, and J. S. Yadav Multimodal Therapy for the Treatment of Severe Ischemic Stroke Combining GPIIb/IIIa Antagonists and Angioplasty After Failure of Thrombolysis Stroke, October 1, 2005; 36(10): 2286 - 2288. [Abstract] [Full Text] [PDF]
|
|